Default: The Lancet Diabetes and Endocrinology

ISSN: 2213-8587

Journal Home

Journal Guideline

The Lancet Diabetes and Endocrinology Q1 Unclaimed

Elsevier BV Netherlands
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Diabetes and Endocrinology is a journal indexed in SJR in Endocrinology and Endocrinology, Diabetes and Metabolism with an H index of 97. It has an SJR impact factor of 9,337 and it has a best quartile of Q1.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Metrics

The Lancet Diabetes and Endocrinology

9,337

SJR Impact factor

97

H Index

256

Total Docs (Last Year)

784

Total Docs (3 years)

4777

Total Refs

5367

Total Cites (3 years)

211

Citable Docs (3 years)

27,58

Cites/Doc (2 years)

18,66

Ref/Doc


Best articles

A story of a golden boy

View more

A time for reflection and thanks

View more

Abdominal lipohypertrophy without insulin injection

View more

ALTITUDE: defining a ceiling for blockade of the renin-angiotensin system?

View more

An artistic awakening

View more

Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial

View more

Association between 25-hydroxyvitamin D and type 2 diabetes

View more

Body language

View more

Bone health in survivors of childhood cancer

View more

Can we safely state that bariatric surgery helps prevent type 2 diabetes?

View more

Cardiovascular health promotion in adolescents: a vital investment

View more

Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists

View more
SHOW MORE ARTICLES

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

View more

Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial

View more

Country in Focus: economic transition and non-communicable diseases in Thailand

View more

Country in Focus: turning the tide of diabetes in Fiji

View more

Diabetes prevention and continuing health-care reform in China

View more

Diabetic foot disease: moving from roadmap to journey

View more

Diabetic kidneys do deserve a lifestyle change

View more

Distal technologies and type 1 diabetes management

View more

Does mortality risk vary among sulfonylureas?

View more

Dying for a good night's sleep

View more

Effect of cancer treatment on hypothalamic-pituitary function

View more

Effectiveness of an mHealth intervention to improve the cardiometabolic profile of people with prehypertension in low-resource urban settings in Latin America: a randomised controlled trial

View more

Comments

No comments ... Be the first to comment!